OBJECTIVE: The need for effective nonhormonal treatments for hot flash management without unwanted side effects continues. The primary aim of this pilot study was to evaluate the effect of combining a nonhormonal pharmacologic agent with a behavioral treatment for hot flash reduction. METHODS:Seventy-one postmenopausal women were randomized to one of four groups: venlafaxine 75mg + hypnosis (VH) versus venlafaxine 75 mg + sham hypnosis (VSH) versus a placebo pill + hypnosis (PH) versus placebo pill + sham hypnosis (PSH). Women recorded hot flash severity and frequency in a daily diary, in real time. The intrapatient difference in hot flash score (frequency × severity) at 8 weeks was analyzed using a General Estimating Equation model, using VSH as the referent arm, controlling for baseline hot flashes. RESULTS: The active arms including PH or VH were not statistically significantly different than VSH (P = 0.34, P = 0.05, respectively). Women in each active arm reported hot flash reductions of about 50%, with the PSH group reporting a 25% reduction. Women receiving the PSH reported statistically significantly smaller reductions in hot flash score than women in the referent VSH arm (P = 0.001). There were no significant negative side effects during the course of the study. CONCLUSIONS: Hypnosis alone reduced hot flashes equal to venlafaxine alone, but the combination of hypnosis and venlafaxine did not reduce hot flashes more than either treatment alone. More research is needed to clarify whether combining hypnosis with a different antidepressant would provide synergistic benefits.
RCT Entities:
OBJECTIVE: The need for effective nonhormonal treatments for hot flash management without unwanted side effects continues. The primary aim of this pilot study was to evaluate the effect of combining a nonhormonal pharmacologic agent with a behavioral treatment for hot flash reduction. METHODS: Seventy-one postmenopausal women were randomized to one of four groups: venlafaxine 75 mg + hypnosis (VH) versus venlafaxine 75 mg + sham hypnosis (VSH) versus a placebo pill + hypnosis (PH) versus placebo pill + sham hypnosis (PSH). Women recorded hot flash severity and frequency in a daily diary, in real time. The intrapatient difference in hot flash score (frequency × severity) at 8 weeks was analyzed using a General Estimating Equation model, using VSH as the referent arm, controlling for baseline hot flashes. RESULTS: The active arms including PH or VH were not statistically significantly different than VSH (P = 0.34, P = 0.05, respectively). Women in each active arm reported hot flash reductions of about 50%, with the PSH group reporting a 25% reduction. Women receiving the PSH reported statistically significantly smaller reductions in hot flash score than women in the referent VSH arm (P = 0.001). There were no significant negative side effects during the course of the study. CONCLUSIONS: Hypnosis alone reduced hot flashes equal to venlafaxine alone, but the combination of hypnosis and venlafaxine did not reduce hot flashes more than either treatment alone. More research is needed to clarify whether combining hypnosis with a different antidepressant would provide synergistic benefits.
Authors: Gary Elkins; Joel Marcus; Vered Stearns; Michelle Perfect; M Hasan Rajab; Christopher Ruud; Lynne Palamara; Timothy Keith Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Kishan J Pandya; Gary R Morrow; Joseph A Roscoe; Hongwei Zhao; Jane T Hickok; Eduardo Pajon; Thomas J Sweeney; Tarit K Banerjee; Patrick J Flynn Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: Debra L Barton; Beth I LaVasseur; Jeff A Sloan; Allen N Stawis; Kathleen A Flynn; Missy Dyar; David B Johnson; Pamela J Atherton; Brent Diekmann; Charles L Loprinzi Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Charles L Loprinzi; Jeff A Sloan; Edith A Perez; Susan K Quella; Phillip J Stella; James A Mailliard; Michele Y Halyard; Sandhya Pruthi; Paul J Novotny; Teresa A Rummans Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Jun J Mao; Annie Chung; Adrian Benton; Shawndra Hill; Lyle Ungar; Charles E Leonard; Sean Hennessy; John H Holmes Journal: Pharmacoepidemiol Drug Saf Date: 2013-01-16 Impact factor: 2.890
Authors: J R Hilditch; J Lewis; A Peter; B van Maris; A Ross; E Franssen; G H Guyatt; P G Norton; E Dunn Journal: Maturitas Date: 1996-07 Impact factor: 4.342
Authors: Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix Journal: JAMA Date: 2011-01-19 Impact factor: 157.335